If you liked this article you might like

Questions Mount at Teva Amid C-suite Change
Allergan Seeks to Reassure Antsy Investors but Will They Buy It?
Some 'January Effect' Stock Picks
Allergan Could Pay $1 Billion for Chase Pharma